Efficacy and Safety of Finerenone in Asian Patients with Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis
Finerenone reduced the risk of CV and kidney events and demonstrated a well-tolerated safety profile in the FIDELITY Asian subpopulation.
Authors
- Bertram Pitt
- Stefan D. Anker (ORCID: https://orcid.org/0000-0002-0805-8683)
- Byung‐Wan Lee (ORCID: https://orcid.org/0000-0002-9899-4992)
- Chien‐Te Lee (ORCID: https://orcid.org/0000-0002-4704-1956)
- Luís M. Ruilope (ORCID: https://orcid.org/0000-0001-6278-7951)
- Meike Brinker (ORCID: https://orcid.org/0000-0002-1560-9535)
- Takashi Wada (ORCID: https://orcid.org/0000-0002-0123-3645)
- Peter R Rossing (ORCID: https://orcid.org/0000-0002-1531-4294)
- Zhihong Liu (ORCID: https://orcid.org/0000-0001-6093-0726)
- Satoshi Yamashita (ORCID: https://orcid.org/0000-0002-6938-9371)
- A. Mann
- Christiane Ahlers
Institutions
- Kanazawa University (JP)
- University of Copenhagen (DK)
- Steno Diabetes Centers (DK)
- Yonsei University (KR)
- University of Michigan (US)
- Nanjing General Hospital of Nanjing Military Command (CN)
- Severance Hospital (KR)
- Centro de Investigación en Red en Enfermedades Cardiovasculares (ES)
- Hospital Universitario 12 De Octubre (ES)
- German Centre for Cardiovascular Research (DE)
- Bayer (Germany) (DE)
- Charité - Universitätsmedizin Berlin (DE)
- Nanjing University (CN)
- Universidad Europea de Madrid (ES)
Publication Details
- Journal
- Kidney Diseases
- Published
- 2025-05-22
- DOI
- https://doi.org/10.1159/000545415
- Citations
- 5
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 6.47
Funders
- Bayer